Aktuelle Therapiekonzepte bei Patienten mit multiplem Myelom

Auch heute noch gibt es für Patienten mit multiplem Myelom kein Therapieverfahren mit einem gesicherten kurativen Potential. Im Gegensatz zu den 70er und 80er Jahren, in denen sich seit Einführung der Therapie mit Melphalan und Prednison durch Alexanian kein relevanter Therapiefortschritt ergeben hat, konnte all durch Etablierung von Hochdosischemotherapie mit Blutstammzelltransplantation eine signifikante Verbesserung der Überlebenszeit bei jüngeren Patienten erreicht werden. Weitere Verbesserungen der Therapieergebnisse haben sich insbesondere durch die Gabe von Bisphosphonaten und α-Interferon ergeben. Vor dem Hintergrund dieser aktuellen Entwicklungen soll ein Überblick über die derzeit möglichen Therapieoptionen bei Patienten mit multiplem Myelom gegeben werden.

Literatur

• 1 Alexanian R, Dimopoulos M A, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma.  Blood. 1992;  80 887-889
• 2 Alexanian R, Dimopoulos M. The treatment of multiple myeloma.  N Engl J Med. 1994;  330 484-489
• 3 Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. intergroupe francais du myelome . A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.  N Engl J Med. 1996;  335 91-97
• 4 Attal M, Payen C, Facon T, Michaux J L, Guilhot F, Moconduit M, Fuzibet J G, Caillot D, Dorvaux V, Harrousseau J L, Cahn J Y, Grobois B, Stoppa A M, Ifrah N, Sotto J H, Pignon B, Bataille R. Single versus double transplant in multiple myeloma: A randomized trial of the »Intergroupe Francais du Myélome« (IFM).  Blood. 1997;  90 (Suppl. 1) 418a
• 5 Aul C, Gattermann N, Germing U, Heyll A. Adverse of interferon treatment. Aul C, Schneider Interferons Springer: Berlin; 1997: 250-266.
• 6 Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents.  N Engl Med. 1984;  310 1351-1360
• 7 Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma.  Stem Cells. 1993;  11 88-94
• 8 Barlogie B, Jagannath S, Vesole D, Tricot G :. Autologous in multiple myeloma. Ammaccon F, Barlogie Multiple myeloma and realted disorders Ares-Serono Symposia: Rom; 1994: 194-216.
• 9 Barlogie B, Jagannath S, Vesole D H, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy vor previously untreated myeloma.  Blood. 1997;  89 789-793
• 10 Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2-mikroglobulin produce a simple and powerful myeloma staging system.  Blood. 1992;  80 733-737
• 11 Belch A R, Eisenhauer E A, Muldal A, Browman G, Klasa R, Osterwalder B. Phase-II study of subcutaneous rhu-interleukin-2 and rhu-interferon alpha-2a in previously treated patients with multiple myeloma.  Ann Oncol. 1995;  6 721-723
• 12 Berenson J R, Lichtenstein A, Porter L, Dimopoulos M, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M J, Blacklock H A, Bell R, Simeone J, Reitsma D J, Heffernan M, Seaman J, Knight R D. Myeloma Aredia Study Group . Efficiacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.  N Engl J Med. 1996;  334 529-530
• 13 von den Berg B C, Lecouvet F E, Michaux L, Labaisse M, Malghem J, Jamart J, Maldague B E, Ferrant A, Michaux J L. Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis.  Radiology. 1996;  201 243-246
• 14 Bergsagel D E, Rider W D. Plasma cell neoplasms. De Vita VT, Hellman S, Rosenberg SA Cancer J. B. Lippincott Company: Philadelphia; 1982: 1439-1475.
• 15 Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperly J, Bladé J, Carlson K, Cavo M, Ferrant A, Goldstone A H, de Laurenzi A, Majolino I, Marcus R, Prentice H G, Remes K, Samson D, Sureda A, Verdonck L F, Volin L, Gahrton G. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the european Group for Blood and Bone Marrow Transplantation.  Blood. 1996;  88 4711-4718
• 16 Björkstrand B, Svensson H, Ljungman P, Apperly J, Goldschmidt H, Remes K, Alegre A, Marcus R, Carlson K, Coser P, Sureda A, Barbui T, Goldstone A H, Bladé J, Volin L, Boogaerts M, Lenhoff S, Majolino I, Samson D, de Laurenzi A, San M iguel JF, Gahrton G. Autologous stem cell transplantation in multiple myeloma - The EBMT registry update.  Bone Marrow Transplant. 1998;  21 (Suppl. 1) 208
• 17 Bladé J, San M iguel JF, Alcalá A, Maldonodo J, Sanz M S, Gracía-CondeJ, Moro M S, Alonso C, Besalduch J, Zubizarreta A, Besses C, González-Brito G, Hernández-Martín J, Fernández-Calvo J, Rubio D, Ortega F, Jiménez R, Colominas P, Faura M V, Font L, Tortosa J, Domingo A, Fontanillas M, Rozman C, Estapé J. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients.  J Clin Oncol. 1993;  11 1165-1171
• 18 Bremer K. Bendamustin a promising alkylating agent non cross-resistant to other alkylators in low grade Non-Hodgkin-Lymphomas.  Onkologie. 1994;  17 (Suppl. 2) 64
• 19 Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedemus M, Ford J, Kandra A. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial.  Br J Haemat. 1998;  101 280-286
• 20 Browman G P, Bergsagel D, Sicheri D, O¿Reilly S, Wilson K S, rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D. Randomized trial of interferon maintenance in multiple myeloma: A study of the national Cancer Institute of Canada Clinical Trial Groups.  J Clin Oncol. 1995;  13 2354-2360
• 21 Cazzalo M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler  L, Essers U, Greil R, Grossi A, Jäger G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin¿s lymphoma: dose finding and identification of predictors of response.  Blood. 1995;  86 4446-4453
• 22 Cook G, Sharp R A, Tansey T, Franklin I M. A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone) an oral equivalent of VAD, as an initial therapy at diagnosis or progression in multiple myeloma.  Br J Haemat. 1996;  93 931-934
• 23 Dimopoulos M A, Barlogie B, Smith T L, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival im multiple myeloma.  Ann Int Med. 1991;  115 931-935
• 24 Durie B G, Salmon S E. A clinical staging system for multiple myeloma.  Cancer (Philad.). 1975;  36 842-854
• 25 Einsele H, Bamberg M, Zander A, Kröger N, Budach W, Schmidt H, Schmidberger H, Hebart H, Trümper L, Müller W, Schlimok G, Hertenstein B, Peest D, Metzner B, Frickhofen N, Kanz L. Total marrow irradiation, busulfan and cyclophosphamide followed by PBSCT in patients with multiple myeloma.  Blood. 1998;  92 (Suppl. 1) 128a
• 26 Glasmacher A, Haferlach T, Gorschlüter M, Mezger J, Maintz C, Clemens M R, Ho Y, Übelacker R, Kleinschmidt R, Gieseler F. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.  Leukemia. 1997;  11 (Suppl. 5) 22-26
• 27 Gregory W M, Richards M A, Malpas J S. Combination therapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials.  J Clin Oncol. 1992;  10 334-342
• 28 Greipp P R, Katzmann J A, O¿Fallon W M, Kyle R A. Value of beta-2-mikroglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.  Blood. 1988;  72 219-223
• 29 Harley J B, Pajak T F, Mcintyre O R, Kochwa S, Cooper M R, Coleman M, Cuttner J. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB.  Blood. 1979;  54 13-22
• 30 Heyll A, Söhngen D, Kobbe G, Schneider P, Bauser U, Thiele K P, Wehmeier A, Südhoff T, Quenzel E M, Rieth C, Wernet P, Fischer J, Frick M, Aul C. Idarubicin, melphalan and cyclophosphamide: An intensified high dose regimen for the treatment of myeloma patients.  Leukemia. 1997;  11 (Suppl. 5) 32-34
• 31 Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Myeloma Group of Estern Sweden . Initial treatment in multiple myeloma: No advantage of multidrug chemotherapy over melphalan-prednisone.  Br J Haemat. 1990;  74 185-191
• 32 Jagannath  S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre F C, Smallwood L, Pruitt K, Dixon D O. Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors.  Blood. 1990;  76 1860-1866
• 33 Joshua D E, Penny R, Matthews J P, Laidlaw C R, Gibson J, Bradstock K, Wolf M, Goldstein D. Australian Leukemia Study Group Myeloma II: A randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.  Br J Haemat. 1997;  97 38-45
• 34 Lathinen R, Laakso M, Palva I, Virkkunen P, Elomaa  I. Finnish Leukaemia Group . Randomized, placebo-controlled multicenter trial of clodronate in multiple myeloma.  Lancet. 1992;  340 1049-1052
• 35 Liebross R H, Ha C S, Cox J D, Weber D, Delasalle K, Alexanian R. Solitary bone plasmocytoma: Outcome and prognostic factors following radiotherapy.  Int J Radiat Oncol Biol Phys. 1998;  41 1063-1067
• 36 Ludwig H, Cohen A M, Polliack A, Huber H, Nachbaur D, Senn H J, Morant R, Eckhardt S, Günczler P, Seewann H L, Schüller J, Rhyner R, Cavalli F, Fritz E. Interferon-alpha for induction an maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies.  Ann Oncol. 1995;  6 467-476
• 37 Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma.  N Engl J Med. 1990;  322 1693-1699
• 38 Medical Research Council Working Party on Leukemia in Adults (Prepared by I.M.C. MacLennan and J. Cusick) . Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis.  Br J Cancer. 1985;  52 153-158
• 39 Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski U H, Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma associated anemia.  Acta Haematol. 1997;  98 204-210
• 40 Moupopoulos L A, Dimopoulos M A, Smith T L, Weber D M, Delsalle K B, Lipshitz H I, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma.  J Clin Oncol. 1995;  13 251-256
• 41 The Nordic Myeloma Study Group . Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma.  Ann Int Med. 124 1996;  212-222
• 42 Österborg A, Boogaerts M A, Cimino R, Essers U, Holowiecki J, Juliusson G, Jäger G, Najman A, Peest D. European Study Group of Erythropoietin . Treatment in multiple myeloma and non-Hodgkin¿s lymphoma.  Blood. 1996;  87 2675-2682
• 43 Österborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jedditehrani M, Ruden U, Lefvert A K, Holm G, Mellstedt H. Idiotype immunization combined with granulocyte-makrophage colony-stimulating factor in myeloma patients induce type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.  Blood. 1998;  91 2459-2466
• 44 Ozaki S, Kosaka M, Watatsuki S, Abe M, Koishihara Y, Matsumoto T. Immuntherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.  Blood. 1997;  90 3179-3186
• 45 Palumbo A, Boccardo M, Bruno B, Tirolo S, Pileri A. Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistent myeloma.  Haematologica. 1994;  79 513-518
• 46 Peest D, Deicher H, Coldewey R, Schmoll H J, Schedel I. Induction and maintenance therapy in multiple myeloma: A multicenter trial of MP versus VCMP.  Eur J Clin Oncol. 1988;  24 1061-1067
• 47 Peest D, Leo R, Bloche S, Hein R, Stannatkiessling S, Tschechene B, Fett W, Harms P, Hoffmann L, Bartl R, Wacker H H, Gorg S, Atzpodien J, Kirchner H, Deicher H. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma.  Br J Haematol. 1995;  89 328-337
• 48 Powels R, Raje N, Cunningham D, Malpas J, Milan S, Horton C, Mehra J, Singhal S, Viner C, Treleaven J. Maintenance therapy for remission in myeloma with Intron-A following melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.  Stem Cells. 1995;  13 (Suppl. 2) 114-117
• 49 Saggio I, Ciappino L, Savino R, Ciliberto G, Perricaudet M. Adenovirus-mediated gene transfer of a human IL-6 antagonist.  Gene Ther. 1997;  4 839-845
• 50 Siegel D S, Deskian K R, Metha J, Singhal S, Fassas A, Munshi N, Anaisse E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G, Barlogie B. Age ist not a prognostic variable with autotransplants for multiple myeloma.  Blood. 1999;  93 51-54
• 51 Singhal S, Metha J, Eddlemon P, Gray P, Cromer J, Desikan R, Ayers D, Siegel D, Munshi N, Anaissie E, Katerjian H, Zeldis J, Barlogie B. Marked anti-tumor effect from antiangiogenesis therapy with thalidomide in high risk refractory multiple myeloma.  Blood. 1998;  92 (Suppl. 1) 318a
• 52 Vesole D H, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J. High-dose therapy for refractory mutliple myeloma: Improved prognosis with better supportive care and double transplants.  Blood. 1994;  84 950-956

Korrespondenz